NEW YORK, March 3, 2022 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced an improved manufacturing process for its pancreatic cancer drug, DHA-dFdC, under license of University of Texas at Austin. The Company also reported the issuance of an additional US patent covering the drug and the filing of a continuation patent application to extend patent coverage to other facets of the drug.
Regarding the manufacturing process, the company reported the successful development of a new means of large-scale production and isolation of the key intermediate compound in the manufacture of DH-dFdC. The company has now signed another contract with its contract manufacturing organization, Parimer Scientific, to use the new process to produce several thousand milligrams of the drug for use in formulation development and stability studies. The company also reported that the US Patent Office recently issued new US Patent No. 11,219,633, which provides additional intellectual property protection for the drug compound. The term of the patent is expected to continue until May 2035 with payment of required maintenance fees. Prior to the issuance of the patent, the Company permitted the timely filing of a patent continuation application, US Serial No. 17/539,682, in which additional claims relating to various aspects of the drug and its formulation will be pursued.
Anthony HayesCEO of AIkido, said, “This new process is a significant step forward in the development of our pancreatic cancer drug and should allow the drug to be produced on a commercial scale at a lower cost. I am also delighted that we can continue to report the expansion of the patent heritage.”
Richard T. Paceowner and principal scientist of Parimer Scientific, said, “The newly developed manufacturing method is a big step forward for this innovative technology. I think it will reduce the unit cost and at the same time increase the batch production volumes.
About AIkido Pharma Inc.
AIkido Pharma Inc. was originally established in 1967 and is a biotechnology company with a diverse portfolio of small molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology sourced from leading universities and researchers, and we are currently developing an innovative therapeutic drug platform through strong partnerships with educational institutions. world-renowned, including the University of Texas in Austin and the University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly looking to expand our pipeline to address unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that could potentially inhibit the replication of several viruses, including influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebola virus and Marburg virus.
Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may”, “could”, “will”, “should”, “believe”, “expect”, “anticipate”, “estimate”, “continue”, “predict”, “plan” , “project”, “” Although the Company believes that these forward-looking statements are reasonable, undue reliance should not be placed on these forward-looking statements, which are based on information available to us as of the date of this release. These forward-looking statements are based on current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the SEC, without limitation to risk associated with its activities contained therein. Accordingly, actual results could differ materially from those currently anticipated, including those regarding our ability to implement our plans, strategies and objectives for future operations. The Company expressly disclaims any obligation to update or change any statements, whether as a result of new information, future events or otherwise, except as required by law.
Brett MaasManaging partner
Phone: (646) 536-7331
E-mail: [email protected]
AIkido Pharma Inc.
E-mail: [email protected]
SOURCEAIkido Pharma Inc.